文献速递胸部肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

同步寡转移非小细胞肺癌根治性放化疗的长期结局

Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution.
PubMed 文献 · Adv Radiat Oncol · 2019-03-22

单中心回顾性分析38例同步寡转移(≤3个转移灶)非小细胞肺癌患者,接受胸部根治性放化疗及全部寡转移灶局部治疗;中位随访54.9个月,中位OS 21.1个月、中位PFS 9.7个月,4年OS率33.7%,≥3级食管炎9%、肺炎5%,脑/中枢神经系统为最常见进展部位。

要点

  • 同步寡转移NSCLC接受根治性胸部放化疗及转移灶局部治疗,生存结局较好且毒性低。
  • 脑/中枢神经系统是最常见进展部位,占任何进展者的57%。
  • 局部区域进展与远处进展均与更差OS独立相关。

核心结论

  • 高区域淋巴结负荷的同步寡转移NSCLC患者接受根治性胸部放化疗可获得较好生存结局和低毒性。

研究设计与样本

  • 单中心回顾性研究纳入1999至2017年38例同步寡转移(≤3个转移灶)NSCLC患者,均接受原发灶及区域淋巴结根治性放化疗。
  • 38例中27例(71%)接受诱导化疗,32例(84%)同步化疗,34例(89%)接受转移灶局部治疗。

主要发现

  • 中位随访54.9个月,84%患者为N2至N3期病变。
  • 中位OS为21.1个月(95%CI 15.6-49.0个月),中位PFS为9.7个月(95%CI 8.2-14.4个月)。
  • 1年、2年、4年OS率分别为75.7%、45.0%、33.7%。
  • 28例出现进展者中16例(57%)为脑/中枢神经系统进展,16例初始脑寡转移者中10例(63%)出现脑/中枢神经系统进展。
  • 多因素分析中局部区域进展(HR 5.8,95%CI 2.2-15.0,P=.0003)和远处进展(HR 6.0,95%CI 2.3-15.4,P=.0002)与更差OS相关。

临床怎么用

  • 对同步寡转移NSCLC可在全身治疗后尽早将胸部根治性放化疗及全部寡转移灶局部治疗纳入整体计划。
  • 治疗期间及治疗后应密切监测中枢神经系统,警惕脑/中枢神经系统进展。

局限性

  • 单中心回顾性研究,样本量38例,结果需谨慎外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We examined long-term clinical outcomes among patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) treated at our institution with definitive thoracic chemoradiation therapy (CRT) and local therapy to all oligometastatic lesions. METHODS AND MATERIALS: A retrospective review identified 38 patients with synchronous oligometastatic NSCLC (≤3 metastatic lesions) who were treated with definitive CRT to the primary tumor and regional lymph nodes between 1999 and 2017 at our institution. Of the 38 patients, 27 patients (71%) received induction chemotherapy, all of whom responded or stabilized with initial systemic therapy before consideration of CRT. Most patients received chemotherapy concurrently with radiation therapy (n = 32; 84%) and local therapy to the metastatic disease site(s) (n = 34; 89%). We assessed patterns of progression or failure, overall survival (OS), progression-free survival (PFS), and toxicities. RESULTS: The median follow-up duration was 54.9 months. Most patients (84%) presented with N2 to N3 disease. The brain or central nervous system was the most common site of disease progression and occurred in 16 of 28 patients (57%) experiencing any progression and 10 of 16 patients (63%) who initially presented with brain oligometastases. Median OS was 21.1 months (95% confidence interval [CI], 15.6-49.0 months), and median PFS 9.7 months (95% CI, 8.2-14.4 months). The 1-, 2-, and 4-year OS rates were 75.7%, 45.0%, and 33.7%, respectively. On multivariate analysis, both locoregional progression (hazard ratio: 5.8; 95% CI, 2.2-15.0; P = .0003) and distant progression (hazard ratio: 6.0; 95% CI, 2.3-15.4; P = .0002), when treated as time-dependent covariates, were associated with inferior OS. Grade ≥3 esophagitis occurred in 9% and grade ≥3 pneumonitis in 5% of patients with evaluable data. CONCLUSIONS: Patients with synchronous oligometastatic NSCLC and a high regional nodal burden treated with definitive thoracic CRT experienced favorable survival outcomes and low toxicity. At our institution, treating oligometastatic disease with CRT after systemic therapy is incorporated into the treatment plan from the onset of therapy, and we monitor the neuraxis closely for progression during and after treatment. Future research should focus on novel treatment combinations, such as immunotherapy or targeted systemic therapy as appropriate to further improve tumor control and survival.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yegya-Raman N, Aisner J, Kim S, et al. Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. Adv Radiat Oncol. 2019. PMID: 31360811. doi:10.1016/j.adro.2019.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。